Indaptus Posts Narrower Loss in Q2
Indaptus Therapeutics (NASDAQ:INDP), a biotechnology company advancing a novel immunotherapy platform for cancer and infectious diseases, reported its second quarter earnings on August 13, 2025. The most significant headline was its narrower-than-expected net loss, reporting a GAAP loss per share of $9.09 for Q2 2025 versus an estimated $9.24. The company remained pre-revenue as anticipated. Its cash position (GAAP) was $6.2 million as of June 30, 2025, and research spending climbed as it expanded its clinical trial program. Overall, the quarter marked steady operational progress, but it underscored persistent liquidity challenges as clinical development costs rise.
Source: Analyst estimates for the quarter provided by FactSet.
Indaptus Therapeutics is a clinical-stage biotech specializing in immunotherapies for cancer and infectious diseases. Its primary development program is Decoy20, an engineered bacterial immunotherapy designed to boost the immune system against tumors. The company is not yet generating product revenue, focusing resources on research and development.
Source Fool.com
